Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort : An Epi-IBD study
© 2018 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd..
BACKGROUND AND AIM: A definitive diagnosis of Crohn's disease (CD) or ulcerative colitis (UC) is not always possible, and a proportion of patients will be diagnosed as inflammatory bowel disease unclassified (IBDU). The aim of the study was to investigate the prognosis of patients initially diagnosed with IBDU and the disease course during the following 5 years.
METHODS: The Epi-IBD study is a prospective population-based cohort of 1289 IBD patients diagnosed in centers across Europe. Clinical data were captured prospectively throughout the follow-up period.
RESULTS: Overall, 476 (37%) patients were initially diagnosed with CD, 701 (54%) with UC, and 112 (9%) with IBDU. During follow-up, 28 (25%) IBDU patients were changed diagnoses to either UC (n = 20, 71%) or CD (n = 8, 29%) after a median of 6 months (interquartile range: 4-12), while 84 (7% of the total cohort) remained IBDU. A total of 17 (15%) IBDU patients were hospitalized for their IBD during follow-up, while 8 (7%) patients underwent surgery. Most surgeries (n = 6, 75%) were performed on patients whose diagnosis was later changed to UC; three of these colectomies led to a definitive diagnosis of UC. Most patients (n = 107, 96%) received 5-aminosalicylic acid, while 11 (10%) patients received biologicals, of whom five remained classified as IBDU.
CONCLUSIONS: In a population-based inception cohort, 7% of IBD patients were not given a definitive diagnosis of IBD after 5 years of follow-up. One in four patients with IBDU eventually was classified as CD or UC. Overall, the disease course and medication burden in IBDU patients were mild.
| Media Type: |
Electronic Article |
|---|
| Year of Publication: |
2019 |
|---|
| Contained In: |
Journal of gastroenterology and hepatology - Vol. 34, No. 6 (2019), p. 996-1003 |
|---|
| Language: |
English |
|---|
| Urls: |
|---|
| Notes: |
Date Completed 06.12.2019 Date Revised 17.12.2019 published: Print-Electronic Citation Status MEDLINE Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine |
|---|
| Physical Description: |
Online-Ressource |
|---|
| doi: |
10.1111/jgh.14563 |
|---|---|
| PMID: |
30562421 |
| PPN (Catalogue-ID): |
NLM292375956 |
|---|
| LEADER | 05801nma a2201285 c 4500 | ||
|---|---|---|---|
| 001 | NLM292375956 | ||
| 003 | DE-601 | ||
| 005 | 20200220174544.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181231s2019 000 0 eng d | ||
| 024 | 7 | |a 10.1111/jgh.14563 |2 doi | |
| 028 | 5 | 2 | |a pubmed20n1017.xml |
| 035 | |a (DE-599)NLM30562421 | ||
| 040 | |b ger |c GBVCP | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Burisch, Johan | |
| 245 | 1 | 0 | |a Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort |h Elektronische Ressource |b An Epi-IBD study |
| 300 | |a Online-Ressource | ||
| 500 | |a Date Completed 06.12.2019 | ||
| 500 | |a Date Revised 17.12.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 500 | |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine | ||
| 520 | |a © 2018 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. | ||
| 520 | |a BACKGROUND AND AIM: A definitive diagnosis of Crohn's disease (CD) or ulcerative colitis (UC) is not always possible, and a proportion of patients will be diagnosed as inflammatory bowel disease unclassified (IBDU). The aim of the study was to investigate the prognosis of patients initially diagnosed with IBDU and the disease course during the following 5 years | ||
| 520 | |a METHODS: The Epi-IBD study is a prospective population-based cohort of 1289 IBD patients diagnosed in centers across Europe. Clinical data were captured prospectively throughout the follow-up period | ||
| 520 | |a RESULTS: Overall, 476 (37%) patients were initially diagnosed with CD, 701 (54%) with UC, and 112 (9%) with IBDU. During follow-up, 28 (25%) IBDU patients were changed diagnoses to either UC (n = 20, 71%) or CD (n = 8, 29%) after a median of 6 months (interquartile range: 4-12), while 84 (7% of the total cohort) remained IBDU. A total of 17 (15%) IBDU patients were hospitalized for their IBD during follow-up, while 8 (7%) patients underwent surgery. Most surgeries (n = 6, 75%) were performed on patients whose diagnosis was later changed to UC; three of these colectomies led to a definitive diagnosis of UC. Most patients (n = 107, 96%) received 5-aminosalicylic acid, while 11 (10%) patients received biologicals, of whom five remained classified as IBDU | ||
| 520 | |a CONCLUSIONS: In a population-based inception cohort, 7% of IBD patients were not given a definitive diagnosis of IBD after 5 years of follow-up. One in four patients with IBDU eventually was classified as CD or UC. Overall, the disease course and medication burden in IBDU patients were mild | ||
| 611 | 2 | 7 | |a Journal Article |2 gnd |
| 653 | 2 | |a Adult |6 D000328 | |
| 653 | 2 | |a Cohort Studies |6 D015331 | |
| 653 | 2 | |a Colectomy |6 D003082 | |
| 653 | 2 | |a Colitis, Ulcerative |6 D003093 |a diagnosis |6 Q000175 |a drug therapy |6 Q000188 |a epidemiology |6 Q000453 |a surgery |6 Q000601 | |
| 653 | 2 | |a Disease Progression |6 D018450 | |
| 653 | 2 | |a Europe |6 D005060 |a epidemiology |6 Q000453 | |
| 653 | 2 | |a Female |6 D005260 | |
| 653 | 2 | |a Follow-Up Studies |6 D005500 | |
| 653 | 2 | |a Humans |6 D006801 | |
| 653 | 2 | |a Inflammatory Bowel Diseases |6 D015212 |a *diagnosis |6 Q000175 |a drug therapy |6 Q000188 |a *epidemiology |6 Q000453 |a surgery |6 Q000601 | |
| 653 | 2 | |a Male |6 D008297 | |
| 653 | 2 | |a Mesalamine |6 D019804 |a therapeutic use |6 Q000627 | |
| 653 | 2 | |a Middle Aged |6 D008875 | |
| 653 | 2 | |a Prognosis |6 D011379 | |
| 653 | 2 | |a Prospective Studies |6 D011446 | |
| 653 | 2 | |a Time Factors |6 D013997 | |
| 655 | 7 | |a inflammatory bowel disease unclassified |2 gnd | |
| 655 | 7 | |a prognosis |2 gnd | |
| 655 | 7 | |a treatment |2 gnd | |
| 655 | 7 | |a Mesalamine |2 gnd | |
| 655 | 7 | |a 4Q81I59GXC |2 gnd | |
| 689 | 0 | 0 | |A f |a Journal Article |
| 689 | 0 | |5 DE-601 | |
| 689 | 1 | 0 | |a inflammatory bowel disease unclassified |
| 689 | 1 | 1 | |a prognosis |
| 689 | 1 | 2 | |a treatment |
| 689 | 1 | |5 DE-601 | |
| 689 | 2 | 0 | |a Mesalamine |
| 689 | 2 | 1 | |A r |a 4Q81I59GXC |
| 689 | 2 | |5 DE-601 | |
| 700 | 1 | |a Zammit, Stefania Chetcuti | |
| 700 | 1 | |a Ellul, Pierre | |
| 700 | 1 | |a Turcan, Svetlana | |
| 700 | 1 | |a Duricova, Dana | |
| 700 | 1 | |a Bortlik, Martin | |
| 700 | 1 | |a Andersen, Karina Winther | |
| 700 | 1 | |a Andersen, Vibeke | |
| 700 | 1 | |a Kaimakliotis, Ioannis P | |
| 700 | 1 | |a Fumery, Mathurin | |
| 700 | 1 | |a Gower-Rousseau, Corinne | |
| 700 | 1 | |a Girardin, Giulia | |
| 700 | 1 | |a Valpiani, Daniela | |
| 700 | 1 | |a Goldis, Adrian | |
| 700 | 1 | |a Brinar, Marko | |
| 700 | 1 | |a Čuković-Čavka, Silvija | |
| 700 | 1 | |a Oksanen, Pia | |
| 700 | 1 | |a Collin, Pekka | |
| 700 | 1 | |a Barros, Luisa | |
| 700 | 1 | |a Magro, Fernando | |
| 700 | 1 | |a Misra, Ravi | |
| 700 | 1 | |a Arebi, Naila | |
| 700 | 1 | |a Eriksson, Carl | |
| 700 | 1 | |a Halfvarson, Jonas | |
| 700 | 1 | |a Kievit, Hendrika Adriana Linda | |
| 700 | 1 | |a Pedersen, Natalia | |
| 700 | 1 | |a Kjeldsen, Jens | |
| 700 | 1 | |a Myers, Sally | |
| 700 | 1 | |a Sebastian, Shaji | |
| 700 | 1 | |a Katsanos, Konstantinos H | |
| 700 | 1 | |a Christodoulou, Dimitrios K | |
| 700 | 1 | |a Midjord, Jóngerð | |
| 700 | 1 | |a Nielsen, Kári Rubek | |
| 700 | 1 | |a Kiudelis, Gediminas | |
| 700 | 1 | |a Kupcinskas, Limas | |
| 700 | 1 | |a Nikulina, Inna | |
| 700 | 1 | |a Belousova, Elena | |
| 700 | 1 | |a Schwartz, Doron | |
| 700 | 1 | |a Odes, Selwyn | |
| 700 | 1 | |a Salupere, Riina | |
| 700 | 1 | |a Carmona, Amalia | |
| 700 | 1 | |a Pineda, Juan R | |
| 700 | 1 | |a Vegh, Zsuzsanna | |
| 700 | 1 | |a Lakatos, Peter L | |
| 700 | 1 | |a Langholz, Ebbe | |
| 700 | 1 | |a Munkholm, Pia | |
| 700 | 0 | |a Epi-IBD group | |
| 773 | 0 | 8 | |i in |t Journal of gastroenterology and hepatology |g Vol. 34, No. 6 (2019), p. 996-1003 |q 34:6<996-1003 |w (DE-601)NLM012635286 |x 1440-1746 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1111/jgh.14563 |3 Volltext |
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2019 |e 6 |c 06 |h 996-1003 | ||